Vaxtex Cotfab Limited
NSE: VCLMarket Closed • NSE
Day range
52 week range
Vaxtex Cotfab Limited closed at INR1.48 (+3.5%) on volume 0.25x its 20-day average, trading 44.36% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -80% QoQ
2024-09-19
AGM Announced
Annual General Meeting
2023-09-07
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.23x
Attractive Valuation: P/E of 5.1x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Textile Manufacturing.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 07 Sept 2023 |
| 24 Jul 2023 | Rights issue | Rights 1:2 @ Premium Re 1.50/- | — | 24 Jul 2023 |
| 15 Feb 2023 | Dividend | ₹2.00 / share | — | 15 Feb 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2022 |
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Titan Company LimitedTITAN Open analysis | ₹3.94L | 68.51 | 0.34% | ₹21,356.00 | ₹1,777.00 | +29.25% | +62.88% |
 Maruti Suzuki India LimitedMARUTI Open analysis | ₹3.61L | 25.20 | 1.22% | ₹52,470.00 | ₹3,447.00 | +35.92% | -9.10% |
Mahindra & Mahindra LimitedM&M Open analysis | ₹3.51L | 17.78 | 1.15% | ₹41,959.00 | ₹3,685.00 | +22.89% | +6.81% |
 Eternal LimitedETERNAL Open analysis | ₹3.00L | 692.13 | 0.00% | ₹3,349.00 | ₹585.00 | +38.79% | -2.82% |
Bajaj Auto LimitedBAJAJ-AUTO Open analysis | ₹2.86L | 24.74 | 1.44% | ₹17,243.72 | ₹2,982.84 | +36.35% | +34.94% |
 Eicher Motors LimitedEICHERMOT Open analysis | ₹2.00L | 34.66 | 1.13% | ₹6,632.00 | ₹1,463.00 | +31.54% | +21.41% |
 TVS Motor Company LimitedTVSMOTOR Open analysis | ₹1.95L | 56.76 | 0.30% | ₹16,296.00 | ₹1,058.00 | +33.46% | +64.54% |
 Samvardhana Motherson International LimitedMOTHERSON Open analysis | ₹1.70L | 38.55 | 0.31% | ₹35,244.00 | ₹1,076.00 | +16.66% | +77.56% |
Incorporated in 2005, Vaxtex Cotfab Ltd is in manufacturing and processing of fabrics of Shirting and Suiting[1]
IndiaConsumer Cyclical
Is Vaxtex Cotfab Limited Shariah compliant?
Vaxtex Cotfab Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (19.35%) complies with AAOIFI threshold (≤ 33%).
What is Vaxtex Cotfab Limited's current valuation relative to peers?
Vaxtex Cotfab Limited trades at a P/E of 5.1x compared to the sector median of 26.8x, and a Price-to-Book of 1.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.23x. Interest coverage is 25.7x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.